A screening assay in the search of an alpha-synuclein PET radioligand

Mathieu Verdurand (1) , Meriem Mendjel-Herda (1) , Elise Levigoureux (1) , Sophie Lancelot (1) , Waël Zeinyeh (1, 2) , Sébastien Alazet (2) , Thierry Billard (2) , Luc Zimmer (1) , Fabien Chauveau (1)

1 BIORAN - Radiopharmaceutical and Neurochemical Biomarkers
2 SURCOOF - Synthèse, Utilisation, Réactivité des Composés Organiques et OrganoFluorés

The accumulation of aggregated α-synuclein (α-Syn) in multiple brain regions is a neuropathological hallmark of synucleinopathies like Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. A pre-mortem diagnosis tool would improve early diagnosis, monitor disease progression and therapeutic efficacy. While suitable amyloid-β (Aβ) PET radiotracers have been developed, no selective α-Syn PET ligand has been identified to date. One PET tracer, BF227, labelled with carbon-11 or fluor-18, has demonstrated interesting binding properties towards α-Syn fibrils in vitro (1) and α-Syn glial inclusions in MSA patients (2).

Domaines: Neurosciences [q-bio.NC]; Imagerie

Mathieu Verdurand, Meriem Mendjel-Herda, Elise Levigoureux, Sophie Lancelot, Waël Zeinyeh, et al.. A screening assay in the search of an alpha-synuclein PET radioligand. World Molecular Imaging Congress (WMIC 2015), Sep 2015, Honolulu, United States. ⟨hal-01207698⟩